A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)

Exclusion Criteria

• •Participant has had chemotherapy within 2 weeks or biological therapy (e.g. bevacizumab) within 4 weeks
• •Participant has not recovered from adverse events from previous therapy within 4 weeks
• •Participant has received EGFR-Tyrosine Kinase Inhibitor (TKI) inhibitor/anti-EGFR mAb therapy
• •Participant has received IGF1R-TKI inhibitor/anti-IGF1R mAB therapy
• •Participant has had more than 2 systemic chemotherapies for metastatic disease
• •Participant has not completed radiotherapy with complete resolution of toxicities at least 2 weeks before starting in the study
• •Participant is taking part in another clinical study
• •Participant has a primary central nervous system tumor
• •Participant abuses drugs or alcohol
• •Participant is pregnant or breastfeeding
• •Participant is Human Immunodeficiency Virus (HIV) positive
• •Participant has a history of hepatitis B or C
• •Participant is using growth hormone or growth hormone inhibitors